Infants2
Medical Emergency
- Rapidly progressive disease
- Complications of end-stage liver disease and premature mortality (<12 months)
All patient images are hypothetical
LAL-D is a rare, genetic disease that causes enzyme deficiency leading to progressive and ongoing multiorgan damage1
Liver and lipid abnormalities in LAL-D overlap with the symptoms of other conditions2
LAL-D testing is widely available2,6
Nearly 50% of patients with LAL-D progress to fibrosis, cirrhosis, or liver transplant within 3 years of first clinical manifestation.7
~100% of patients with LAL-D have liver consequences.1
LDL-C levels in LAL-D are comparable to other hereditary dyslipidemias.11
Early testing is critical, and you can test for LAL-D with a simple blood test.2,6
Abbreviations: ALT, alanine aminotransferase; LAL-D, lysosomal acid lipase deficiency; LDL-C, low-density lipoprotein cholesterol; NAFLD, non-alcoholic fatty liver disease.
References: 1. Bernstein DL, et al. J Hepatol. 2013;58(6):1230-1243. 2. Reiner Ž, et al. Atherosclerosis. 2014;235(1):21-30. 3. Elleder M, et al. J Hepatol. 2000;32(3):528-34. 4. Vom Dahl S, et al. J Hepatol. 1999;31(4):741-6. 5. Valayannopoulos V, et al. Mol Genet Metab. 2017;120(1-2):62-66. 6. Lukacs Z, et al. Clinica Chimica Acta. 2017;471:201-205. 7. Burton BK, et al. Curr Med Res Opin. 2017;33(7):1211-1214. 8. Vos MB, et al. J Pediatr Gastroenterol Nutr. 2017;64(2):319-334. 9. Chalasani N, et al. Hepatology. 2018;67(1):328-357. 10. Burton BK, et al. J Pediatr Gastroenterol Nutr. 2015;61(6):619-625. 11. Pericleous M, et al. Lancet Gastroenterol Hepatol. 2017;2:670-679.
*All fields are required
By clicking Submit, I agree to the Terms of Use